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Digital platforms play a critical facilitating role in 
the “changing models of biomedical research” and 
clinical care. Such platforms integrate disparate data 
sources and formats—including genetic, health, 
genealogical, and increasingly lifestyle data—into 
more accessible, searchable, and computationally 
efficient structures for basic scientific research, as well 
as for clinical care. Genetic platforms involve 
unprecedented data management challenges because 
of their scale and multidimensionality. Still, little 
research has been conducted on genetic platforms. 
Leveraging secondary data on  three interlinked 
genetic platforms, we pursue a data perspective on 
platform evolution and entrepreneurial strategies. We 
contribute to the discussion on the design and 
evolution of digital platforms that considers 
responsible data use. 
 
1. Introduction  
 
"Genomics is at the crossroads where data and 
biology meet."  
Li Ge, chairman of WuXiNextCODE, 2017. 
    
During the twentieth century, digital technologies 
fundamentally disrupted businesses and social 
communities. During the twenty-first century, biology 
promises to alter life, death, and their pathways. 
Genetics opens doors for fundamental changes in the 
ways we understand diseases and their mechanisms. 
But these revolutions in biology at large, and in 
genetics in particular, are closely intertwined with 
disruptions in digital technologies.  
Genetic platforms are enabled by digital 
technologies. In genetics, data represent the blood line 
that makes possible new research discoveries and that 
enable new treatment possibilities and care solutions in 
clinical practice. Genetic platforms facilitate the 
collection, storage, and analysis of large-scale genetic 
data with phenotypical and behavioral data.  Since the 
mapping of the human genome project completed in 
2003, data centric models have begun emerging that 
offer a compelling complement to basic scientific 
biomedical research and to the classic drug 
development models, as well as to care delivery [7]. 
Genome-wide association studies require access to 
large-scale genetic databases that allow the comparison 
of people who have a particular disease with those who 
do not have the disease. Personalized precision care 
requires the ability to integrate genetic data with 
detailed phenotypical data from medical records and 
family history. And consumer personal genetics 
companies like 23andMe are giving individuals direct 
access to their own genetic data, marketed as a form of 
entertainment about family history, which can be 
informative about an individual’s health risks [27, 29].  
Annas and Elias [2] predict that in a few years, “a 
majority of health plans will make it easy for their 
members to have their entire genomes sequenced and 
linked to their electronic health records and will 
provide software to help people interrogate their own 
genomes, with or without the help of their physicians 
or a genetic counselor supplied by the health plan.”  
Although genetic platforms populate daily news 
headlines, they have attracted little interest apart from 
the genetic data controversies and disputes related to 
medical, ethical, legal, security, and privacy concerns 
[3, 4, 30]. The concerns with data include informed 
consent, information privacy, the right to withdraw 
consent, the obligation to give feedback to study 
participants, benefit sharing arrangements, secondary 
uses of genetic data, and possible access to data by 
governments, public safety authorities, and insurance 
companies [5,10]. Although these issues are clearly 
important, the platforms themselves have drawn little 
interest. Even when the objective has been to 
commercialize genetic data, the focus has been on the 
loss of trust, restrictions on researcher and public 
access, and conflicts of public and private interests.  
The role of digital platforms has not been explored. 





Meanwhile, the information systems and 
technology management literature has focused on 
digital platforms but not on genetic platforms and not 
on data more broadly speaking [13, 32]. Development 
toolkits that give access to and analyze data streams are 
discussed in terms of their applications  and the size of 
the platform’s potential market. But the toolkits and 
applications, rather than the data, are in the limelight. 
In health information technology literature, digital 
platforms and infrastructures have been examined in 
terms of coordinating access to care, facilitating 
knowledge transfer, and improving operational 
efficiencies [23]. What has been missing is the role of 
digital platforms in cultivating new scientific 
discoveries and treatment knowledge. 
Admittedly, well-funded “triple-helix” partnerships 
involving government entities, corporations, and 
universities have tried to build genetic databanks for 
the scientific community, but some of these efforts 
have faltered in the face of restrictive national 
regulations and relentless controversies [30].  
Framingham Genetic Medicine (FGM) provides 
one case in point [19, 24, 26, 31]. FGM was a for-
profit venture with 20% ownership by Boston 
University. FGM aimed to digitize data from the 
Framingham heart study, conducted by Boston 
University under contract from the National Heart, 
Lung, and Blood Institute. Starting in 1948, the study 
gathered panel data on more than 5,000 residents of 
Framingham, MA. Boston University continued the 
study after the NIH contract expired; an additional 
5,000 Framingham residents were recruited. Through 
the years, the study yielded valuable research results 
and a vast quantity of potentially valuable but largely 
manual data about the subjects’ health and lifestyles. 
The FGM venture was formed in 2000 to digitize the 
data. FGM planned to conduct genetic “linkage 
studies” “similar to those being done by Gemini 
Genomics (Cambridge, UK) and deCODE Genetics 
(Reykjavik, Iceland)…” [16] and to fund the entire 
effort by providing data access to pharmaceutical firms 
for drug discovery research. FGM failed because NIH 
insisted that genetic data collected using public funds 
had to remain open for use by other researchers--a 
condition that would preclude a period of privileged 
access for fee-paying drug companies. Concerns about 
privacy were also raised, although the dispute about 
exclusive access to data is what ultimately resulted in 
the collapse of the effort.   
Other failed efforts include the UmanGenomics in 
Sweden. The effort involved a grant of exclusive 
commercial rights (but not exclusive access) to an 
existing, publicly owned, research biobank; and 
consent for such use and access was secured from the 
participating individuals. New consent had to be 
secured for individual projects that exceeded the scope 
of the existing consent. Despite being heralded as a 
model of ethical conduct, fights over intellectual 
property rights   brought the venture down [30].  
Other more recent partnerships are following an 
open science and drug discovery approach (including 
genetic analysis), such as the effort at the Montreal 
Neurological Institute at McGill University. Here, 
researchers maintain the intellectual property rights to 
their research outputs [28].1 
Publicly funded efforts increasingly are 
complemented by entrepreneurial firms with bold 
initiatives to build genetic platforms. Although left 
unexamined, these efforts are socially significant and 
important. The efforts can have ramifications beyond 
healthcare because they involve unprecedented big 
data management challenges, the application of 
artificial intelligence, and a whole host of social, legal, 
and ethical issues that together shape the platforms and 
their evolution.  
 
2. Related Literature 
 
Before examining three interlinked tales of genetic 
platforms being built by entrepreneurial firms, we 
briefly review selected literature on digital platforms 
and genetic data banks.  
 
2.1. Digital Platforms 
 
Digital platforms provide a shared set of services and 
architecture. The architecture includes technological 
modular systems and multiple actors in “multi-sided” 
roles [36, 38]. Digital platforms draw on various digital 
infrastructures, such as cloud computing and data 
analytics. Platforms take on many forms, but here we 
focus on platform ecosystems that are “more complex 
than either a product family or a multisided market” 
[35]. The study of platform ecosystems is important 
because these systems can lead to new markets, new 
industries, or in the case of science, new knowledge 
domains or even specialties. Recent research highlights 
how digital platforms can facilitate opportunity 
formation, creation, and scaling of entrepreneurial 
ventures [8, 18, 42].   
Research on digital platforms has taken either a 
market or technological perspective [13]. A market-
based perspective starts with a focus on demand and 
examines transactions, network effects, and 
competition; value is created from matching supply 
and demand and pricing. The focus is on competition 
between platforms and how economics of scope in 




demand can create value. In the market perspective, the 
primary role of the platform is as a coordinating device 
(IOS and Android platforms are classic examples), and 
“the existence of the platform itself is also taken for 
granted, exogenous and unchanging” [Gawer, 2014, p. 
1241]. Although the possible competition and 
collaboration between platforms is recognized, how 
that competition shapes the emergence and evolution 
of platforms is rarely examined. 
A technological perspective takes a supply 
perspective and focuses on stable components, such as 
modules and functions in technological architectures. 
Value is created from reusing components for new 
combinations and other forms of co-creation that 
increase the growth of offerings. Variety in the 
innovation process expands the economies of scope 
and generates greater value through the platform. Just 
as in the market perspective, the platform is a 
coordinating device, but the platform adds value on the 
supply side rather than the demand side, promoting 
innovations among the technology development 
community through various toolkits and application 
programming interfaces (APIs). Here again, the IOS 
and Android platforms, as well as various maker 
platforms such as Shapeways, serve as examples.  
Similarly to the market perspective, the 
technological perspective provides little insight into the 
emergence and evolution of platforms over time. When 
the focus is on evolution, it is limited to what happens 
with specific components or modules and does not 
consider the platform overall.   
Neither the market nor the technological 
perspective focuses on data except as something 
enabled by the APIs or toolkits. In their review paper 
on digital platforms, Schreieck et al. [32] state that “no 
article explicitly analyzes the role of data as a 
boundary resource in platform ecosystems.” The 
authors found this lacuna surprising because so many 
digital platforms are fueled by data sales.  
Admittedly, IS research at large is not devoid of a 
data perspective. Some research examines the creation 
of business value from large-scale and real-time digital 
data streams [25]. However, the focus is on specific 
applications and the effect of data streams on specific 
firms, rather than on platform ecosystems. Existing 
research also examines organizational data supply 
chains from the legal and societal perspectives, 
including privacy, ownership, and security [21]. Where 
data have been the focus, attention has been directed 
mainly to open government data or to data governance.   
 
2.2. Genetic Databanks 
 
Data governance was the focus of a study by 
Vassilakopoulou, Skorve, and Aanestad [39] on two 
different breast cancer genes. The authors chronicle the 
emergence of data repositories that involve varying 
governance based on public, private, and walled garden 
models. The oldest initiative was set up as a public 
commons to further the goal of open sharing of all 
existing datasets; in this initiative, “registration was 
open to all and access to registered users was 
unrestricted” [39, p. 7]. However, major labs stopped 
contributing, claiming that the quality of the data in the 
repository was poor. Meanwhile, the initiative 
involving private control has become the world’s 
largest service—at least partially because of its use of 
multiple methods, advanced infrastructures, and rapid 
testing procedures.    
The study is important because it can be used to 
begin to extrapolate a data perspective to complement 
the market and technological perspectives in the digital 
platform literature (see Table 1). The platforms are 
conceptualized by Vassilakopoulou et al. as databanks, 
data commons, and data repositories. Vassilakopoulou 
et al. emphasize discovery and advances in scientific 
knowledge (e.g., cancer biology) and clinical 
knowledge (e.g., better diagnoses of cancer 
susceptibility) as the key goals. The value is created 
through large-scale and varied data on inheritance and 
environmental influences from diverse sources.   
 
TABLE 1. Perspectives on digital platforms 
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Although both market and technological 
perspectives view platforms as fixed and stable at the 
broader platform level, Vassilakopoulou et al. shed 
light on the evolution of databanks, including how one 
databank stimulates the growth of another and how 
databanks compete. Evolution is influenced not just by 
the arrival of new actors and their datasets but also by 
                                                 
2 The columns of economics and engineering are adapted 
from Gawer (2014). 
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sociotechnical design decisions. Decisions that affect 
data quality influence the evolution of platforms.  
Vassilakopoulou et al.’s study also raises many 
other issues, such as intellectual property protection 
and legal and ethical concerns that shape the 
databanks. Technology is largely in the background, 
although the importance of computational techniques 
in improving data quality, access, and analysis and in 
increasing the benefits to the researchers is 
acknowledged. However, fragmentation of the data 
persists because of the use of home-grown protocols, 
processes, and tools for gathering, storing, and 
interpreting genetic data across different research 
groups. And data sharing in the research communities 
remains selective.  
Other research on genetic databanks echoes 
concerns over quality of genetic data. Lee [20] points 
out that the likelihood of errors in genetic data is 
relatively high, “accentuating the need for manual 
oversight and verification…. Correcting, updating, and 
adding value to existing data records remain critical 
challenges.” Data quality issues become even more 
complex when health and medical records need to be 
merged with genetic records to support clinical 
research and, ultimately, clinical practice. For instance, 
Gainer and Cagan [12] report that the codes used by 
clinicians to designate patient diseases in electronic 
medical records often describe possible rather than 
definitive diagnoses: They primarily serve 
administrative and billing purposes and might not be 
accurate enough for research purposes. For example,  
the Partners Personalized Medicine initiative required a 
sizable data science effort to develop algorithms for 
proper disease classifications of medical records, 
according to reports. 
 Below, we explore further the data perspective by 
examining three interlinked entrepreneurial initiatives 
to advance genetic platforms. 
 
3. Three Tales of Genetic Platforms 
 
The initial focus in our study was on controversies 
surrounding genetic databanks and their 
commercialization. We followed newspaper articles in 
regional and national newspapers. The articles caught 
our attention because we were already studying issues 
such as data protection and data responsibility. 
DeCODE Genetics was acknowledged as a bold 
scientific venture that had gone farther than any other 
in the commercialization of genetic data, and it had 
become a reference point for most discussions of 
genetic data commercialization [41].  Following up on 
the deCODE story led us to NextCode and 
WuxiNextCode. We then searched for the customers of 
NextCode and found our third platform example. 
Hence, the platforms were not chosen randomly but 
instead resulted from an inquiry that followed the 
principles of the snowball method. To understand the 
entrepreneurial genetic platforms, we relied primarily 
on secondary data. The data perspective emerged in 
our study when we triangulated our analysis with the 
existing literature on digital platforms.  
 
3.1 deCODE: Genetic population database for 
Icelanders  
 
This entrepreneurial venture had its start in 1996 in 
Iceland when deCODE’s iconic founder, Kari 
Stefansson (KS), formerly a neurologist at Harvard 
Medical School, received $12 million from seven U.S. 
venture capital (VC) firms to build a trio of linkable 
databanks that leveraged Iceland’s wealth of medical, 
genetic, and genealogical information. The building of 
three linked databases was an ambitious and high-risk 
vision to generate new scientific discoveries, drugs, 
and treatments. Hence, the company’s market entry 
point was data.  
Initially, deCODE Genetics sought to control 
access to the databases it built about Icelandic citizens 
using government financial support. deCODE’s 
founder justified the exclusivity arrangement by 
referencing the expense and commercial risk of genetic 
and drug discovery research. deCODE’s arrangement 
with the Icelandic government gave the company an 
interest in any commercial product resulting from 
research using the data [22]. The plans were to sell data 
access and research to pharmaceutical companies.  
The first task involved turning Iceland’s 
genealogical records into searchable form. These 
records stretched back 1,000 years and were in the 
public domain. In addition to automating genealogical 
records, deCODE planned to build the first population-
wide genome database in the world by collecting 
samples from the entire population. In addition, the 
new venture proposed to automate the country’s 
medical records.  
Hoffman-La Roche Pharmaceuticals provided 
initial venture funding and bought the rights to 
manufacture any drugs developed by deCODE. 
deCODE filed an IPO in 2000 but had mixed results 
because of the international controversy that then 
surrounded its data plans. KS explained: “Because we 
were a commercial entity from the start, we had both 
the regulatory entities and the scientific community in 
Iceland and abroad concerned” [1].   
To build the proposed (but never completed) health 
database, KS solicited the help of Iceland’s legislative 
entity, the Alþingi. He convinced the entity to pass a 
statute authorizing the transfer of personal medical 
records (dating back to 1911) from doctors and health 
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centers to deCODE. In the process, deCODE would 
computerize Iceland’s system of medical records [14].  
In 1998, deCODE received from the Icelandic 
government a 12-year exclusive license for 
construction and commercialization of the database. 
The licensing terms included deCODE’s exclusive 
access to the database, exclusive rights to generate 
findings from it, and the right to sell the findings to 
parties chosen by deCODE. According to the statute, 
only assumed, rather than informed, consent was 
required from citizens. Individuals could opt out by 
filling out official forms, but any data already in the 
database would not have to be removed [9, 11, 14].  
Concerns over ethics, privacy, and security 
generated more than 700 news articles on deCODE in 
Iceland alone, and many more overseas. The exclusive 
privatization agreement authorized by Iceland’s 
government authorities led to outcries from researchers 
concerned about their future access to the data. A 
statement from the chairman of the Icelandic Medical 
Association’s ethics council read [33]: “When you put 
genealogical information into the data bank and also 
genetic data, then the data bank knows more about you 
than you know about yourself.” Many members of the 
medical community refused to turn over their patients’ 
health records. The Data Protection Commission was 
not convinced of the adequacy of its security. Citizens 
as well as concerned parties outside of Iceland were 
angered by the lack of informed consent protocols. The 
storm culminated in 2000 when a 15-year-old girl filed 
a lawsuit because her dead father’s medical records 
were to be entered into the database, which she 
considered a violation of her privacy. The lawsuit 
triggered the Icelandic Supreme Court to rule the 
Health Sector Database Act unconstitutional. The court 
ruling halted the further construction of a centralized 
health database.  
When deCODE’s centralized database plan failed, 
the firm switched to a distributed approach that 
leveraged individual research projects and their data 
requirements to collect data samples. deCODE enlisted 
the cooperation of the informal owners of the relevant 
health data by inviting local physicians to participate as 
researchers in its projects. These physicians then 
brought their patients to the studies. The company ran 
tens of research studies in parallel “under the strictest 
standards of informed consent” [41, pp. 94-95]. The 
firm reported 95% participation rates in the studies, 
and 90% of participants signed the broader consent 
form. Such high rates of participation were unheard of 
around the world, including in the United States. By 
2002, statements were made suggesting that, to some 
extent, “a [health] database now exists inside 
deCODE” [41]. These developments also were aided 
and supported by those in Iceland who donated their 
blood samples. Encouragement to participate was seen 
by some as patriotic in building a biological 
powerhouse in the North Atlantic, while others viewed 
the high levels of participation as indicative of 
“coercion” because many Icelandic citizens had 
heavily invested in deCODE shares [4]. 
During the mid-2000s, the company sought to 
become a full-fledged biotech company. Continuing to 
build its downstream capabilities, deCODE partnered 
with both Merck and Bayer. The company also 
invested heavily in its technological capabilities. It 
partnered with IBM and strengthened its computing 
and data mining technologies.   
 In the late 2000s, however, investors in deCODE 
grew impatient. The firm filed for bankruptcy in 2009, 
selling data access and technological assets to another 
private entity, while much of the company’s 
management team remained intact. The startup focused 
on selling direct-to-consumer genetic testing kits to 
accelerate the collection of data samples, but it 
encountered significant pushback from the medical 
community and regulators. In 2010, deCODE 
downsized from 750 people to 125 people. All 
downstream activities were sold off.  The company 
focused on basic scientific research.  
In 2012, Amgen acquired deCODE. With Amgen 
came independence, stability, and the financial 
resources needed to focus on fundamental research that 
would leverage access to the population-based data of 
about 120,000 Icelanders. According to the editor of 
Nature Genetics, some 5% of the journal’s cumulative 
articles since 2000 have been authored by deCODE 
researchers. deCODE itself claims to have published 
more than 400 articles across various outlets [1].  
In 2013, data and research activities were separated 
from proprietary technologies, and the latter were 
incorporated into a venture called NextCODE. The 
new platform venture was legally and commercially 
separate from the access to data. The data were owned 
by the Icelandic government and had to remain in 
Iceland.   
 
3.2.  WuXiNextCODE:  Global Platform of 
Open Data with Proprietary Infrastructures 
In 2015 NextCODE merged with a division of 
WuXi,3 a Chinese contract research company, to form 
WuXiNextCODE. WuXi provided access both to large 
farms of sequencing machines and to the Chinese 
market. 
In the two years since the merger, WuXiNextCODE 
has built the leading large-scale, integrated, global 
genetics platform, with strong cloud-based computing, 
                                                 
3 WuXi is used here to correspond to WuXiPharma and 
WuXiApptech.  
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deep learning, and elastic relational database 
infrastructures. The platform is positioned as a bridge 
between research and clinical care, and the goal is to 
expand the overlap between the two. To turn genetic 
data into actionable knowledge for a person’s treatment 
plans can require linking millions of different 
individuals’ genomes. Genome sequencing and 
research feed directly into clinical care, and clinical 
care feeds comprehensive patient health information 
back into research.  
WuXiNextCODE’s proprietary technology includes 
a relational database architecture and an artificial 
intelligence engine. It is based on streaming data and is 
unrivaled in its efficiency in the storage and processing 
of genomic joins. The technology is versatile in 
accessing data in varied formats, including from web 
pages. The platform offers a workbench and interactive 
query tools for researchers and clinicians. 
Although the platform’s infrastructure technologies 
are proprietary, the platform promotes global sharing 
through open data access to any registered user. The 
platform manages the largest genome cohort database 
in the world. Hence, WuXiNextCODE has already 
accomplished what its rivals, including the FDA and 
the National Institute of Standards and Technology, 
have been trying to achieve for years.  
The WuXiNextCODE platform has enabled new 
research collaborations and expedited clinical trials 
across projects and countries. For example, the 
platform collaborates with Huawei and its “China 
precision medicine cloud.”4 The platform is now in use 
in population genomics projects, precision medicine 
applications, and clinical diagnosis and wellness in 
China, England, Ireland, the United States, Qatar, and 
Singapore. In the United States, the platform is in use 
at Boston’s Children’s Hospital and Cincinnati 
Children’s Hospital. In its partnership with Shanghai 
Children’s Hospital, the WuXiNextCODE platform 
sequences some two million genomes annually. The 
company offers several products in Chinese markets, 
including a whole-genome wellness service for 
Chinese consumers. The company currently is going 
through an IPO filing in China.   
3.3. START: Open source genetic research 
database with voluntary resources 
In 2007, Anthony Tolcher left the UT Health 
Science Center in San Antonio to start up South Texas 
Accelerated Research Therapeutics (START) with two 
other colleagues. Today, START is one of the largest 
oncology treatment practices in the San Antonio area 
and a leading independent (i.e., unaffiliated with an 
                                                 
4 http://www.bio-itworld.com/2016/5/24/wuxi-nextcode-
huawei-launch-precision-medicine-cloud-china.aspx 
academic medical center) cancer research and drug 
development center. In fact, START (with centers also 
in the upper midwest, Europe, and Asia) has arguably 
become the world leader in Phase I clinical trials for 
oncology—an area of activity long dominated by 
academic medical centers.  
As an unaffiliated cancer center, START had access 
to tumor samples only from its own patients. Tissue 
samples in tumor banks are held by academic medical 
centers and are available only to researchers at those 
centers. (The U.S. National Cancer Institute operates 
open-access tissue banks, but these repositories lack 
comprehensive healthcare data.)   
To increase its access to tumor samples for clinical 
research, Tolcher and his colleagues at START 
announced in 2010 the establishment of a San Antonio 
cancer tumor bank, funded by private donors. Unlike 
affiliated tumor banks, the START’s tumor bank was 
to be open access—meaning that cancer researchers 
anywhere in the world could gain access to START’s 
“consented” tissue samples (i.e., samples from patients 
who had given appropriate written consent). The open 
access nature of the START tumor bank was intended 
to encourage cancer researchers around the world to 
contribute their patients’ consented tissue samples, thus 
accelerating research.  
Developing the tumor bank required substantial 
investment. Communicating the idea to the local 
oncology community took time. In addition, START 
had to develop new procedures for obtaining patient 
consent, obtaining associated medical records data, 
collecting and transporting samples to the bank, and 
releasing samples for preclinical research. All these 
efforts were successful. Since 2010, START’s tumor 
bank has become the world’s largest repository of 
samples of a certain rare cancer; it receives samples 
weekly from around the world. In addition, START 
researchers have published widely in the cancer 
research literature and have received numerous 
prestigious awards. 
The success of START’s tumor bank positioned it 
well for its next major donor-funded initiative in 2012. 
Known as the San Antonio 1000 Cancer Genome 
Project (SA1KCGP), it is an open access database of 
genomic data from 1,000 consenting patients. After an 
early partnership with Beijing Genomics, Inc. (BGI), 
START signed on with WuXiNextCODE for low-cost, 
high-volume genetic sequencing, informatics support, 
and cloud data storage. In early 2017, START was 
more than halfway to its goals in terms of the number 
of samples collected and sequenced and the funds 
raised for genetic sequencing and analysis.  
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High-quality medical records data, when linked 
with genetic samples and data, offer significant 
advantages for drug discovery—and high-quality 
electronic health records (EHR) data are scarce. First, 
the coding of diseases in clinical EHR systems 
typically is designed for insurance reimbursement 
purposes and is not of sufficient quality for research 
needs. Second, the many commercially available EHR 
systems do not easily connect with one another. To 
illustrate, Partners Healthcare in Boston has spent 
billions to implement common EHR systems across its 
hospitals to support its clinical practice and research on 
personalized medicine. Even so, it also has had to 
make considerable investments in bioinformatics 
analysis to ensure adequate diagnostic coding. NIH 
genetic data, although open to researchers around the 
world, offer only limited medical/health/phenotypic 
data. Thus, if START is able to offer tumor samples, 
genetic data, and high-quality clinical data, it would 
indeed have a valuable resource. 
To get there, START faced the challenge that non-
START contributors (e.g., local health care providers 
whose patients’ consented samples are sent to 
START’s tumor bank for research) used many 
different and incompatible EHR systems. To overcome 
this challenge, START developed a proprietary 
software tool, called Clinical Synchrony (trademarked 
in 2013) for retrieving and standardizing clinical data, 
including both treatment and survival data. Clinical 
Synchrony extracts relevant data from providers’ 
systems and loads it into vendor Medidata’s Rave (a 
cloud-based clinical data management system) in a 
common format, so that it can be searched and 
analyzed.  
The next challenge is to provide researchers with a 
“data portal” that allows them to easily search and 
analyze linked genomic and clinical data. START’s 
genomic data currently are curated on the 
WuXiNextCODE platform; START’s clinical data are 
stored in Medidata’s Clinical Cloud. Researchers need 
an easy way to access the two systems in tandem. Both 
WuXiNextCODE and Medidata have expressed 
interest in developing START’s data portal.  
 To date, START has no paid staff dedicated to its 
open source genetic data program. START researchers 
are participating in the effort as a collateral assignment. 
START’s scientific contributions are considerable. 
In 2016 alone, its researchers presented 31 papers and 
abstracts at a major cancer conference (American 
Society of Clinical Oncology, 2016). Although START 
is not affiliated with any university medical school, it 
sponsors resident visiting scientists.  
Table 2 compares the three platforms. 
 
 
Table 2. Comparison of the three platforms 
 
4. Discussion 
The tales of deCODE, WuXiNextCODE, and 
START’s SA1kCGP show how genetic platforms 
contribute to “changing models of biomedical 
research” [7] and clinical care. The platforms facilitate 
the access to large data sets and the analysis of genetic 
data combined with detailed phenotypical data from 
medical records and family history. Increasingly, these 
platforms would be expected to include behavioral 
monitoring data from daily activities (e.g., fitness and 
nutrition data). The entrepreneurial initiatives operate 
at the edges of traditional health care systems. The 
platform owners and key architects are neither large 
university research hospitals nor governments. The 
initiatives have exhibited considerable flexibility and 
adaptability to leverage technologies and combine 
varied data or samples with other datasets. To varying 
extents, the initiatives also have been able to 
commercialize their research results in the form of 
products and therapies in the market. But the initiatives 
continue to face many concerns and to experience 
many tensions.  
The three genetic platforms have adopted different 
governance models. deCODE tightly controlled data 
access and commercialization rights. Its investments 
were privately funded. In contrast, START’s cancer 
genome project has offered open access to data to 
encourage voluntary contributions. The investments 
were funded by financial donations and donations of 
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time and energy. In the case of the WuXiNextCODE 
platform, a mixed open–closed data model is followed 
in which researchers maintain and curate the data they 
provide but gain access to large volumes of data about 
human genetic variants and phenotypes provided 
through the platform. The platform allows researchers 
to circumvent the nonstandard tools, technical 
incompatibilities, and data conversions that have 
previously hampered genetic databanks. 
The differences in the governance models and 
strategies deployed in these platforms were influenced 
by differing goals and internal and external constraints. 
deCODE pursued bold scientific discoveries that 
required improved access to genetic and health data. 
The firm realized early on that the phenotypic data 
from medical records and family history were critical 
to rendering genetic data useful for research. The firm 
sought to build three linkable databases (i.e., 
genealogy, health, and genetic) covering the entire 
population of Iceland. Two of the databases were 
ultimately built, but the health database was scuttled in 
the wake of international controversies. However, a 
change in strategy helped deCODE to reach its goal. 
deCODE began working directly with physicians to 
gain access to patients for participation in research 
studies. As Winickoff [41] reported, “…[deCODE] had 
found a way to amass large amounts of health 
information and samples by traditional methods—
methods that did not require building the [centralized 
health system data] architecture for Iceland.” 
START required high-quality data to carry out its 
main business of clinical trials for treatments. Its lack 
of affiliation with medical schools and government 
agencies created a scarcity of data, which the company 
resolved by embarking on its own platform initiative. It 
also relied heavily on existing networks with its cancer 
clinics and  broadened these networks using an open 
access approach. Unencumbered by the institutional 
barriers associated with universities and government 
agencies, START has been able to move fast. Also, its 
local practitioner networks provided access to samples 
that represent a spectrum of disease states; thus, 
START data have not been limited to the most 
advanced cases of disease that characterize many 
university repositories. (The most difficult cases often 
are referred to university hospitals.) START built a 
technical architecture and open access governance 
model that encouraged contributions of tumor samples 
and genetic data. And START’s investment in the 
Clinical Synchrony tool allowed clinical medical 
record data to be merged into the database. Hence, the 
different goals and starting points resulted in different 
governance options. These governance options, in turn, 
influenced the nature of the regulations and 
controversies that surrounded the platforms.  
The evolving regulations and controversies shaped 
the overall evolution of the platforms. Many 
governments around the world restricted (or even 
prohibited) exclusive commercial access to data 
gathered by public national health programs; the 
Icelandic government did so as well, although not 
initially. Independent researchers feared losing access 
to research data if deCODE retained exclusive access 
rights. The medical community mounted opposition to 
deCODE’s plans, including its attempts to enter the 
direct-to-consumer genetic testing market. The 
reliability of the tests, the value of the tests, and the 
citizens’ ability to understand the long-term 
ramifications of such tests were particularly 
questioned. Concerns about data privacy and the 
security of individuals’ health data culminated in a 
major change from a centralized data initiative to a 
much more distributed undertaking. 
After Amgen acquired deCODE, the digital 
platform was separated from the access to data. The 
platform  provided a new pathway to 
commercialization. The technology was much less 
contested and regulated, compared to the data.  
deCODE developed a myriad of new technologies 
involving major patented inventions for the platform. 
The large scale of its database and the 
multidimensionality of the genetic and phenotype data 
rendered traditional data formats and database 
structures inadequate. deCODE partnered with vendors 
to develop its AI capabilities for the platform.  
The initiatives also highlight how issues related to 
data quality shaped the evolution of the platforms. 
Although deCODE and START used different 
governance models in their platforms, each exhibited 
tight controls in data gathering and records 
management to reduce the data quality problems 
known to threaten both genomic data and phenotypic 
data. Such challenges have implications not only for 
the technical design of genetic databanks, but also for 
the rules governing data contributions and 
modifications.  
The pursuit of high-quality data in genetic 
platforms created optimism that entrepreneurial 
ventures might promote data sharing for research and 
clinical care. The success of emerging approaches to 
clinical and translational research depends significantly 
on improved platforms of genetic and health data, 
which in turn require greater collaboration and data 
sharing among researchers and clinicians. Still 
researchers are reluctant to share the data they have 
collected and analyzed [15]. For example, researchers 
might comply with norms and rules for rapid 
publication of genetic sequence data [20] but then 
exclude the phenotypic data that would make genetic 
data much more useful for research. Even when 
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researchers are motivated to share their data, they are 
constrained by the need to protect patient 
confidentiality and to follow data security provisions. 
These concerns suggest the need for access controls to 
ensure that only appropriate uses of databank resources 
are allowed. Meanwhile, even modest access 
restrictions can seriously impede the “open science” 
goals of genetic databanks and platforms [6]. 
Designing governance arrangements that promote 
contributions, ensure data quality, and encourage 
innovative and responsible data use is a difficult 
balancing act, and the need for such a design approach 
represents promising opportunities for future research.  
Although platforms certainly need to facilitate data 
sharing, research also needs to examine how the 
platforms shape research collaborations and the 
research questions pursued in such collaborations. How 
does the composition of research teams shape the 
platforms? Both deCODE and START show 
remarkable levels of international collaboration, as 
well as significant research productivity.  
Another avenue of future research would explore 
how the platforms collaborate, compete, and trigger the 
formation of new platforms. Generativity needs to be 
examined at the platform level. START partnered with 
WuXiNextCODE for genome sequencing and 
infrastructure services (e.g., cloud storage services), 
but START is also pursuing its own open platform, 
including an access portal. How will these initiatives 
complete or collaborate with public large-scale 
national and global data-sharing efforts [17, 40]? 
We close by returning to the digital platform 
literature. Although the platform literature has shed 
much light on the market and technological 
perspectives, the data-centric perspective is lacking. 
The room for further developing this perspective is 
abundant. For example, future studies need to examine 
meaning-making systems for the data; such systems 
not only can circumscribe the data but also control how 
such platforms facilitate new meanings. That is, 
algorithms and other tools intended to convert data into 
actionable knowledge become bounded by these 
semantic meaning-making knowledge structures [37].  
Hence, although the platforms we have discussed here 
offer promising early steps, much research is needed to 
understand strategies and governance arrangements for 
digital platforms to promote scientific discoveries and 
treatments while maintaining the necessary security 
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